Skip to main content
. 2016 Sep 16;7(45):73781–73791. doi: 10.18632/oncotarget.12064

Table 3. Univariate analysis of patient treatment outcome.

N/Events Median P-valuea 1 year 2 years 3 years HR (95% CI) P-valueb
Total OS Surgery STR + NTR 153/150 12 0.000* 19.6 2 2 1
GTR 328/288 11 36.3 14.2 10.2 0.667(0.545-0.817) 0.000*
Radiotherapy No 283/270 9 0.000* 24.7 3.5 3.5 1
Yes 198/168 12 39.9 18.9 14.2 0.643(0.528-0.782) 0.000*
Genotype G/G 301/276 11 0.207 28.2 9 6.8 1
A/G 150/146 12 37.2 11.8 9.8 0.847(0691-1.038) 0.11
A/A 24/22 10 25 16.7 0 0.998(0.647-1.542) 0.994
G/G 301/276 11 0.108 28.2 9 6.8 1
A/A + A/G 180/162 11 35.6 12.5 8.8 0.865(0.712-1.050) 0.143
Total PFS Genotype G/G 299/286 8 0.107 13 5.7 4.1 1
A/G 154/143 8 20.8 10.4 6.5 0.824(0.674-1.088) 0.059
A/A 24/24 8 16.7 8.3 0 0.944(0.622-1.431) 0.785
G/G 299/286 8 0.044* 13 5.7 4.1 1
A/A + A/G 178/167 8 20.2 10.1 5.6 0.839(0.693-1.016) 0.073
I-II grade OS Surgery STR + NTR 97/95 12 0.001* 21.6 14 14 1
GTR 197/168 11 39.6 16.1 12.5 0.677(0.522-0.878) 0.003*
Radiotherapy No 170/160 10 0.000* 28.2 4.7 0 1
Yes 124/103 12 39.5 19.8 16.3 0.665(0.517-0.855) 0.001*
III-IV grade OS Surgery STR + NTR 56/55 9 0.002* 16.1 1.8 1.8 1
GTR 131/120 10 32.8 11.3 6.9 0.624(0.451-0.864) 0.004*
Radiotherapy No 113/110 9 0.001* 19.5 1.8 0 1
Yes 74/65 12 40.5 17.6 11.3 0.617(0.450-0.864) 0.003*

Notes:

a

P-values based on the log-rank test;

b

P-values based on the Wald test;

*

p-value < 0.05 indicates statistical significance.

Abbreviations: GTR: gross-total resection; NTR: near-total resection; STR: sub-total resection; OS: Overall Survival; PFS: Progression-free Survival.